No Data
No Data
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?
PANTHERx Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA (Olezarsen)
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $62
Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
Express News | Ionis Pharmaceuticals Inc : Oppenheimer Raises Target Price to $78 From $75